04 September 2019
Visiongain has launched a new pharma report Cell Therapy Market Report 2019-2029: By Type (Autologous, Allogeneic), by Product (Equipment, Consumables, Software, Other Services), by End User (Hospitals, Clinics) and by Region.
Global cell therapy market is anticipated to grow on account of rising government investments in cell-based R&D, growing oncology-oriented cell-based therapy clinical trials, and growing prevalence of chronic diseases among other contributing factors. The global cell therapy market is anticipated to grow at a lucrative CAGR of 5.4% and anticipated to reach USD 9.56 Billion by 2029.
Regenerative Medicine is the science of replacing damaged tissue or organ with a healthy cell using sophisticated instruments like cell therapy, tissue engineering, and gene therapy. There is a global paradigm change from chemical medicines to the implementation of biological therapies on a large scale. These biological therapies are emerging as an option to some of the health problems earlier untreated, such as late-stage disease, juvenile diabetes, and heart failure.
Until the early 2000s, the market was dominated by chemotherapeutic drugs such as cancer chemotherapeutic agents, biguanides for diabetes, and many more that were produced in bulk quantities, meeting the requirements of large population. Traditionally, market players followed the bulk production pattern for these drugs, which fit the requirements of the market. With the evolving times, however, and advances in biotechnology, applied sciences have substituted the traditional patterns of drug growth that gave rise to new biological medicines.
Overall, cell therapy is experiencing an increase in R&D operations with enormous efforts from focused small-to mid-segment companies. While the market is filled with dermatological (particularly anti-aging) and musculoskeletal therapies, Novartis ' approval of Kymriah and Gilead's approval of Yescarta led to a new lease of life for earlier unresolved cancer cases.
In August 2018, the European Commission granted Novartis marketing authorization for Kymriah to become only company with approved CAR-T cell therapy for 2 distinct indications in the U.S. and the European Union. Following the footsteps of Novartis and Gilead, BlueBird Bio obtained an accelerated evaluation of its cutting-edge gene treatment LentiGlobinTM, a serious sickle cell cancer treatment, by the Committee for Medicinal Products for Human Use (CHMP) and the European Medicines Agency (EMA), in July 2018
Similarly, companies like Celgene, Juno Therapeutics and Tigenix are moving in the same direction either with their in-house pipeline of novel cell therapies or by acquiring niche players. For example, in June 2018, for a whopping USD 9 billion, Celgene purchased Juno, gaining access to Juno's upcoming CAR-T cell treatment. This followed Gilead's USD 11.9 billion acquisition of Kite Pharma, gaining access to their CART cell therapy Yescarta, which has now been marketed.
North America holds majority of market share followed by Europe and will continue to dominate in the future due to growing number of research projects in the region, coupled with funding for research institutes from the government. On the other hand, APAC is anticipated to grow with the highest CAGR over the forecast period and is emerging as an important region supporting cell therapy research activities with numerous local firms such as Kangstem Biotech, Pharmicell and Mesoblast having potential product launches in coming 5-7 years.
Currently, key players are forming various strategies such as acquisitions, mergers, partnerships, collaborations and launching new products to strengthen their position in the global single-cell genomics market. Companies are also expanding their R&D, distribution, and management facilities to expand their business and to hold a competitive edge in the market.
For example, one of the most prominent Chinese cell therapy firms is Nanjing-based Legend Biotech, which reported impressive information from last year's anti-BCMA CAR-T therapy at ASCO and signed a $350 million treatment agreement with Johnson & Johnson at the end of 2017. The Chinese FDA approved the clinical trial application of the company in March, making LCAR-B38 M the first cell therapy in China to enter clinical trials.
The comprehensive market report features companies such as ANTEROGEN.CO.,LTD, Beckman Coulter, Inc. (Subsidiary of Danaher Corporation), Becton, Dickinson and Company, Capricor Therapeutics, Celgene Corporation, Cellectis, Cells for Cells, Cellular Dynamics, Celyad, CESCA Therapeutic, DiscGenics, Fibrocell Science, Inc., Gamida Cell, GE Healthcare,
JCR Pharmaceuticals Co., Ltd., Kolon TissueGene, Inc., Lonza Group, MEDIPOST, Merck KGaA, Miltenyi Biotec GmbH, Novadip Biosciences, NuVasive, Inc., Osiris Therapeutics, Inc., OxStem, PHARMICELL Co., Ltd, ReNeuron Group plc, Sartorius, Stemcell Technologies, Takeda Pharmaceuticals, Terumo Bct, Inc. (A Subsidiary of Terumo Corporation), and Vericel Corporation among other prominent players.
Also the research study offers market estimation and forecast for the period ranging 2019–2029 for global markets such as North America, Latin America, Western Europe, Eastern Europe, Asia Pacific and MEA along with regional sub-markets as U.S., Canada, Brazil, Mexico, Germany, UK, France, Italy, Spain, Nordic, Benelux, Russia, Poland, India, Japan, China, Australia, ASEAN, GCC, South Africa and North Africa.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Diagnostic imaging technology such as MRI and CT scans has become more precise and accessible, due to which radiology has increasingly become a key foundation of modern medicine.
20 September 2019
Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.
10 September 2019
The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.
09 September 2019
Thyroid disease is one of today’s most prevalent hormonal illnesses. Hyperthyroidism, hypothyroidism, and thyroid nodules are the most common thyroid gland disorders.